IP Library › Granted Patent US 12,263,249
Granted Patent B2
US 12,263,249 · App. 17/364,770 · Granted Apr 1, 2025

Formation of particles including agents

Inventors: Chase Spenser Coffman (Newton, MA); Lyndon Fitzgerald Charles, Jr. (Medford, MA); Paul Brown (Boston, MA); Daniel Benjamin Dadon (East Boston, MA); Lisa Liu (Somerville, MA); Cory Robinson (Cambridge, MA); Dale Arlington Thomas, III (Hampden, ME)
Assignee: Elektrofi, Inc.
A61K9/145A61K9/146B01J2/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,263,249
App. No.
17/364,770
Granted
Apr 1, 2025
Kind
B2
Abstract

The invention provides methods for the preparation of particles including one or more agents, e.g., therapeutic or diagnostic agents. The particles can be formed by creating droplets of a first liquid, e.g., including an agent, and removing the first liquid, e.g., through its dispersal in a second liquid and/or evaporation, to solidify the droplets. Advantageously, the process of forming the particles does not significantly alter the structure or activity of the agents and may enhance the stability of the agents. For example, the particles may be stored for long periods of time without significant loss of activity, and in some embodiments, without the need for refrigeration. These particles may be used to generate stabilized pharmaceutical compositions for storage or other logistical purposes, pharmaceutical suspensions, pharmaceutical powder formulations (e.g., inhalable powders, injectable powders), creams or other topical pastes, nutraceuticals, or cosmetics.

Claims (22)

1. A composition comprising particles, wherein a plurality of particles are round particles having a sphericity greater than 0.9, wherein the plurality of particles comprise an excipient and a therapeutic agent, wherein a mass loading of the therapeutic agent in the plurality of particles is between 50% and 100%, wherein the therapeutic agent is a protein, peptide, or nucleic acid, and wherein the excipient is a salt, an amino acid, a surfactant, or a carbohydrate.

2. The composition of claim 1 , wherein the composition has a concentration of Subvisible Particles of less than 10,000,000 per mL, wherein the Subvisible Particles are insoluble upon reconstitution in water.

3. The composition of claim 2 , wherein the Subvisible Particles have a characteristic size greater than or equal to 10 um and are at a concentration of less than 6,000 per mL.

4. The composition of claim 2 , wherein the Subvisible Particles have a characteristic size greater than or equal to 25 μm and are at a concentration of less than 600 per mL.

5. The composition of claim 1 , wherein the therapeutic agent has 0.5 to 1.0 activity per unit.

6. The composition of claim 1 , wherein the particles have diameters from 0.1 to 1000 μm.

7. The composition of claim 1 , wherein the therapeutic agent is an antibody or fragment thereof.

8. The composition of claim 1 , wherein the particles have less than 10% aggregation of the therapeutic agent in suspension or upon reconstitution in water.

9. The composition of claim 1 , wherein the particles have less than 10% fragmentation of the therapeutic agent in suspension or upon reconstitution in water.

10. The composition of claim 1 , wherein the particles have less than 50% change in charge variants of the therapeutic agent compared to the therapeutic agent prior to particle formation in suspension or upon reconstitution in water.

11. The composition of claim 1 , wherein the particles are formed by a method comprising:

providing droplets comprising an aqueous first liquid and an antibody or fragment thereof;

contacting the droplets with an organic solvent, wherein the droplets float or do not float on the organic solvent; and

allowing the droplets to dry, thereby forming the particles.

12. The composition of claim 11 , wherein the particles have less than 10% by weight of the aqueous first liquid remaining after drying.

13. The composition of claim 11 , wherein the particles have less than 10% by weight of the organic solvent remaining after drying.

14. The composition of claim 11 , wherein the aqueous first liquid is selected from the group consisting of water, 0.9% saline, lactated Ringer's solution, dextrose 5%, and a buffer.

15. The composition of claim 11 , wherein the organic solvent is selected from the group consisting of benzyl benzoate, acetone, ethyl lactate, dimethyl isosorbide, dimethyl sulfoxide, glycofurol, diglyme, methyl tert-butyl ether, polyethylene glycol, 2-pyrrolidone, tetrahydrofurfuryl alcohol, trigylcerides, methyl acetate, ethyl acetate, propyl acetate, butyl acetate, amyl acetate, chloroform, dichloromethane, ethanol, methanol, propanol, butanol, acetonitrile, diethyl ether, diglyme, 1,2-dimethoxyethane, dimethylformamide, pentane, toluene, and any combination thereof.

16. The composition of claim 1 , wherein the salt is selected from the group consisting of sodium chloride, calcium chloride, potassium chloride, sodium hydroxide, magnesium sulfate, sodium glucoheptonate, sodium pertechnetate, and guanidine hydrochloride.

17. The composition of claim 1 , wherein the amino acid is selected from the group consisting of alanine, aspartic acid, cysteine, isoleucine, glutamic acid, leucine, methionine, phenylalanine, pyrrolysine, serine, selenocysteine, threonine, tryptophan, tyrosine, valine, asparagine, L-arginine, histidine, glycine, glutamine, or a combination thereof.

18. The composition of claim 1 , wherein the surfactant is selected from the group consisting of polysorbate, magnesium stearate, sodium dodecyl sulfate, polyethylene glycol nonaphenyl ether, glycerin, or polyoxyethylated castor oil.

19. The composition of claim 1 , wherein the carbohydrate is selected from the group consisting of dextran, trehalose, sucrose, agarose, mannitol, lactose, sorbitol, or maltose.

Assignments (2)
CHANGE OF NAME Recorded Feb 2, 2026
From: ELEKTROFI, INC.
To: HALOZYME HYPERCON, INC.
Reel/Frame 073662/0717 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2021
From: COFFMAN, CHASE SPENSER; CHARLES, LYNDON FITZGERALD, JR.; BROWN, PAUL; DADON, DANIEL BENJAMIN; LIU, LISA; ROBINSON, CORY; THOMAS, DALE ARLINGTON, III
To: ELEKTROFI, INC.
Reel/Frame 057000/0234 →
Continuity (4)
Division 16633097
Provisional Application 62676195 · May 24, 2018
Provisional Application 62536746 · Jul 25, 2017
Related Publication 20210322317A1 · Oct 21, 2021
References Cited (200)
US 3013007A · Dale et al. · 1961 [cited by applicant]
US 3882036A · Krezanoski et al. · 1975 [cited by applicant]
US 4172896A · Uno et al. · 1979 [cited by applicant]
US 4531056A · Labowsky et al. · 1985 [cited by applicant]
US 5358970A · Ruff et al. · 1994 [cited by applicant]
US 5427798A · Ludwig et al. · 1995 [cited by applicant]
US 5541231A · Ruff et al. · 1996 [cited by applicant]
US 5595721A · Kaminski et al. · 1997 [cited by applicant]
US 5612055A · Bedford et al. · 1997 [cited by applicant]
US 5677180A · Robinson et al. · 1997 [cited by applicant]
US 5731000A · Ruff et al. · 1998 [cited by applicant]
US 5736137A · Anderson et al. · 1998 [cited by applicant]
US 5763493A · Ruff et al. · 1998 [cited by applicant]
US 5840731A · Mayer et al. · 1998 [cited by applicant]
US 6095134A · Sievers et al. · 2000 [cited by applicant]
US 6110973A · Young · 2000 [cited by applicant]
US 8013022B2 · Deangelo et al. · 2011 [cited by applicant]
US 8512754B2 · Needham · 2013 [cited by applicant]
US 8728525B2 · Brown et al. · 2014 [cited by applicant]
US 8779094B2 · Johnston et al. · 2014 [cited by applicant]
US 8939388B1 · Beetz et al. · 2015 [cited by applicant]
US 9259701B2 · Palmer et al. · 2016 [cited by applicant]
US 9364542B2 · Chang · 2016 [cited by applicant]
US 9643996B2 · Petrel et al. · 2017 [cited by applicant]
US 11077059B2 · Coffman et al. · 2021 [cited by applicant]
US 11459376B2 · Brown et al. · 2022 [cited by applicant]
US 11510995B2 · Sanchez Martin et al. · 2022 [cited by applicant]
US 11654112B2 · Coffman et al. · 2023 [cited by applicant]
US 11717488B2 · Brown et al. · 2023 [cited by applicant]
US 11795429B2 · Bitterfield et al. · 2023 [cited by applicant]
US 12115262B2 · Coffman et al. · 2024 [cited by applicant]
US 20020081732A1 · Bowlin et al. · 2002 [cited by applicant]
US 20030055010A1 · De Haan · 2003 [cited by applicant]
US 20040197469A1 · Lyons et al. · 2004 [cited by applicant]
US 20050186183A1 · Deangelo et al. · 2005 [cited by applicant]
US 20060147400A1 · Piot · 2006 [cited by applicant]
US 20080026068A1 · Brown et al. · 2008 [cited by applicant]
US 20080095849A1 · Wu et al. · 2008 [cited by applicant]
US 20090035381A1 · Stankus et al. · 2009 [cited by applicant]
US 20090274765A1 · Beduneau et al. · 2009 [cited by applicant]
US 20100092526A1 · Baker et al. · 2010 [cited by applicant]
US 20100092778A1 · Watanabe · 2010 [cited by examiner]
US 20100330169A1 · Bunick et al. · 2010 [cited by applicant]
US 20120076800A1 · Dai et al. · 2012 [cited by applicant]
US 20120157591A1 · Rufner et al. · 2012 [cited by applicant]
US 20130256931A1 · Palmer et al. · 2013 [cited by applicant]
US 20140052020A1 · Allen et al. · 2014 [cited by applicant]
US 20140262694A1 · Knigge · 2014 [cited by applicant]
US 20140263694A1 · Lin et al. · 2014 [cited by applicant]
US 20140271843A1 · Ma et al. · 2014 [cited by applicant]
US 20140288282A1 · Petrel et al. · 2014 [cited by applicant]
US 20140303356A1 · Gramer et al. · 2014 [cited by applicant]
US 20140308270A1 · Lobo et al. · 2014 [cited by applicant]
US 20140348852A1 · Vos et al. · 2014 [cited by applicant]
US 20140378370A1 · Johnston et al. · 2014 [cited by applicant]
US 20140378655A1 · Anderson · 2014 [cited by applicant]
US 20150079395A1 · Cruise et al. · 2015 [cited by applicant]
US 20150157576A1 · Shum et al. · 2015 [cited by applicant]
US 20160128944A1 · Chawrai et al. · 2016 [cited by applicant]
US 20160250329A1 · Bukrinski et al. · 2016 [cited by applicant]
US 20160271064A1 · Sell et al. · 2016 [cited by applicant]
US 20180333493A1 · Shenoy · 2018 [cited by applicant]
US 20190374470A1 · Coffman et al. · 2019 [cited by applicant]
US 20200253875A1 · Coffman et al. · 2020 [cited by applicant]
US 20210220289A1 · Coffman et al. · 2021 [cited by applicant]
US 20210309724A1 · Brown et al. · 2021 [cited by applicant]
US 20210315827A1 · Brown et al. · 2021 [cited by applicant]
US 20210403599A1 · Badovinac-Crnjevic et al. · 2021 [cited by applicant]
US 20220211627A1 · Arrighi et al. · 2022 [cited by applicant]
US 20220389084A1 · Brown et al. · 2022 [cited by applicant]
US 20230065628A1 · Auer et al. · 2023 [cited by applicant]
US 20230094393A1 · Charles et al. · 2023 [cited by applicant]
US 20230181473A1 · Auer et al. · 2023 [cited by applicant]
US 20230338299A1 · Paul et al. · 2023 [cited by applicant]
US 20230355530A1 · Coffman et al. · 2023 [cited by applicant]
US 20240255517A1 · Carter et al. · 2024 [cited by applicant]
US 20240270864A1 · Brown et al. · 2024 [cited by applicant]
US 20240293332A1 · Brown et al. · 2024 [cited by applicant]
US 20240415782A1 · Coffman et al. · 2024 [cited by applicant]
CN 1750811A · 2006 [cited by applicant]
EP 0677332A2 · 1995 [cited by applicant]
EP 2773330B1 · 2020 [cited by applicant]
JP 2008266128A · 2008 [cited by applicant]
JP 2010524948A · 2010 [cited by applicant]
JP 2011079747A · 2011 [cited by applicant]
JP 2013166100A · 2013 [cited by applicant]
JP 2014058466A · 2014 [cited by applicant]
JP 2014129357A · 2014 [cited by applicant]
WO 9911196A1 · 1999 [cited by applicant]
WO 0335301A1 · 2003 [cited by applicant]
WO 2006087354A2 · 2006 [cited by applicant]
WO 2008062908A1 · 2008 [cited by applicant]
WO 2008092084A2 · 2008 [cited by applicant]
WO 2010044867A1 · 2010 [cited by applicant]
WO 2010082543A1 · 2010 [cited by applicant]
WO 2011131943A2 · 2011 [cited by applicant]
WO 2012042274A1 · 2012 [cited by applicant]
WO 2014057424A2 · 2014 [cited by applicant]
WO 2015085898A1 · 2015 [cited by applicant]
WO 2015138844A1 · 2015 [cited by applicant]
WO 2015196091A1 · 2015 [cited by applicant]
WO 2016014497A1 · 2016 [cited by applicant]
WO 2016089309A1 · 2016 [cited by applicant]
WO 2017106716A1 · 2017 [cited by applicant]
WO 2018098376A1 · 2018 [cited by applicant]
WO 2019023392A1 · 2019 [cited by applicant]
WO 2019226969A1 · 2019 [cited by applicant]
WO 2020051307A1 · 2020 [cited by applicant]
WO 2020160323A2 · 2020 [cited by applicant]
WO 2021050953A1 · 2021 [cited by applicant]
WO 2021158959A2 · 2021 [cited by applicant]
WO 2021168271A1 · 2021 [cited by applicant]
WO 2021212019A1 · 2021 [cited by applicant]
WO 2022256840A2 · 2022 [cited by applicant]
WO 2024177927A1 · 2024 [cited by applicant]
Allahham, D. et al., “Development and application of a micro-capillary rheometer for in-vitro evaluation of parenteral injectability,” Journal of Pharmacy and Pharmacology, vol. 56; 709-716 (2004). [cited by applicant]
Aniket et al., “MicroglassificationIM: A novel technique for protein dehydration,” J Pharm Sci. 103(3): 810-820 (2014). [cited by applicant]
Banerjee et al., “Electrospray ionization mass spectrometry: a technique to access the information beyond the molecular weight of the analyte,” Int J Anal Chem. Article 282574 (2012) (40 pages). [cited by applicant]
Bock et al., “Electrospraying of polymers with therapeutic molecules: state of the art,” Prag Polym Sci. 37(11): 1510-1551 (2012)(67 pages). [cited by applicant]
Bogelein et al., “Cyclone selection influences protein damage during drying in a mini spray-dryer,” Int J Pharm. 401(1-2): 68-71 (2010). [cited by applicant]
Capelle, M.A.H. et al., “High throughout screening of protein formulation stability: Practical considerations,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 65; 131-148 (2007). [cited by applicant]
Clackson, T. et al., “Making antibody fragments using phage display libraries,” Nature vol. 352; 624-628 (1991). [cited by applicant]
Cloupeau et al., “Electrohydrodynamic spraying functioning modes: a critical review,” J Aerosol Sci. 25(6): 1021-1036 (1994). [cited by applicant]
Cloupeau et al., “Electrostatic spraying ofliquids: Main functioning modes,” J Electrostat. 25(2): 165-184 (1990). [cited by applicant]
CN Search report Mailed on Jul. 28, 2022 for CN Application No. 202080012222. [cited by applicant]
Dias et al., “Tolerability of High-Volume Subcutaneous Injections ofa Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects,” AAPS PharmSciTech. 16(5): 1101-1107 (2015). [cited by applicant]
Elektrofi, Inc., Redefining the Delivery of Biologics, 11 pages, retrieved from Internet URL: https://www.elektrofi.com/welcome#technology on Nov. 15, 2021. [cited by applicant]
English Translation of CN Office Action Mailed on Aug. 3, 2022 for CN Application No. 202080012222. [cited by applicant]
English translation of CN Search Report mailed Jul. 28, 2022 for CN Application No. 2020800122229. [cited by applicant]
European Search Report and Search Opinion Received for EP Application No. 18838118, mailed on May 6, 2021, 12 pages. [cited by applicant]
Fernandez de la Mora et al., “The current emitted by highly conducting taylor cones,” J Fluid Mech. 260: 155-184 (1994). [cited by applicant]
Fernandez de la Mora et al., “The fluid dynamics of Taylor cones,” Annu Rev Fluid Mech. 39: 217-43 (2007) (29 pages). [cited by applicant]
Forgacs, E. et al., “Direct (Normal)-Phase High-Performance Liquid Chromatography,” Chapter II.B. in Molecular Basis of Chromatographic Separation, CRC Press, Baco Raton, FL; 120-131 (1997). [cited by applicant]
Galam et al., “High-throughput assay for the identification ofHsp90 inhibitors based on Hsp90dependent refolding of firefly luciferase,” available in PMC Mar. 1, 2008, published in final edited form as: Bioorg Med Chem.… [cited by applicant]
Ganan-Calvo et al., “Current and droplet size in the electrospraying ofliquids. Scaling laws,” J Aerosol Sci. 28(2): 249-275 (1997). [cited by applicant]
Gapinski et al., “Structure and dimensions of core-shell nanoparticles comparable to the confocal vol. studied by means of fluorescence correlation spectroscopy,” Langmuir. 32(10): 2482-2491 (2016). [cited by applicant]
Gikanga et al., “Manufacturing of High-Concentration Monoclonal Antibody Formulations via Spray Drying-the Road to Manufacturing Scale,” PDA J Pharm Sci Technol. 69(1): 59-73 (2015) (16 pages). [cited by applicant]
Giugliano et al., “Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a ra… [cited by applicant]
Hickey, J.W. et al., “Biologically Inspired Design ofNanoparticle Artificial Antigen-Presenting Cells for Immunomodulation,” Nano Letters, vol. 17; 7045-7054 (2017). [cited by applicant]
Hui et al., “Progress in preparation of peptide protein drug microspheres,” The medicine herald, Issue 10, 2007, pp. 1-32. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US18/43774, mailed on Feb. 6, 2020, 10 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US18/43774, mailed or Oct. 3, 2018, 12 pages. [cited by applicant]
Janssen Biotech Inc., “Highlights of prescribing information,” <http://www.janssenlabels.com/package-insert/product-monograph/prescribinginformation/DARZALEX-pi.pdl>, dated Jul. 2019, retrieved on Aug. 22, 2019 (13 page… [cited by applicant]
Jones, A.J.S., “Analysis of Polypeptides and Proteins,” Advanced Drug Delivery Reviews, vol. 10; 29-90 (1993). [cited by applicant]
Kaltashov et al., “Electrospray ionization mass spectrometry can provide estimates of protein surface areas in solution, ” available in PMC Jan. 27, 2009, published in final edited form as: Anal Chem. 77(16): 5370-5379 … [cited by applicant]
Kim et al., “Controlled production of emulsion drops using an electric field in a flow-focusing microfluidic device,” Appl Phys Lett. 91: 133106 (2007) (3 Pages). [cited by applicant]
Ku et al., “Electrospray characteristics of highly viscous liquids,” J Aerosol Sci. 33(10): 1361-1378 (2002). [cited by applicant]
Lal et al., “Clean western blot signals from immunoprecipitated samples,” available in PMC Jan. 25, 2006, published in final edited form as: Mol Cell Probes. 19(6): 385-388 (2005) (5 pages). [cited by applicant]
Lavorini et al., “New inhaler devices—the good, the bad and the ugly,” Respiration. 88(1): 3-15 (2014). [cited by applicant]
Lee et al., “Solid-state stabilization of a-Chymotrypsin and catalase with carbohydrates,” Ind Eng Chem Res. 45(14): 5134-5147 (2006). [cited by applicant]
Li et al., “Effects of pulsed electric fields and heat treatment on stability and secondary structure of bovine immunoglobulin G,” J Agric Food Chem. 53(3): 663-670 (2005). [cited by applicant]
Longman et al., “Identifying differences in solution Conformations ofhvo chimeric IgG3 antibodies through triple detection SEC,” LCGC North America. 18(21): (2006) (5 pages). [cited by applicant]
Lopez-Herrera et al., “Coaxial jets generated from eleclified Taylor cones. Scaling laws,” J Aerosol Sci. 34(5): 535-552 (2003). [cited by applicant]
Lopez-Herrera et al., “Coaxial jets generated from electrified Taylor cones. Scaling laws,” J Aerosol Sci. 34(5): 535-552 (2003). [cited by applicant]
Loscertales et al., “Micro/nano encapsulation via electrified coaxial liquid jets,” Science. 295(5560): 1695-8 (2002). [cited by applicant]
Makadia et al., “Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier,” Polymers (Basel). 3(3): 1377-1397 (2011). [cited by applicant]
Marks, J.D. et al., “By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage,” J. Mol. Biol., vol. 222; 581-597 (1991). [cited by applicant]
Miller et al., “Antibody nanoparticle dispersions formed with mixtures of crowding molecules retain activity and in vivo bioavailability,” available in PMC Oct. 1, 2013, published in final edited form as: J Pharm Sci. 1… [cited by applicant]
Miller et al., “Low viscosity highly concentrated injectable nonaqueous suspensions of lysozyme microparticles,” available in PMC Feb. 17, 2011, published in final edited form as: Langmuir. 26(2): 1067-1074 (2010) (22 p… [cited by applicant]
Moghadam et al., “Electro-spray of high viscous liquids for producing mono-sized spherical alginate beads,” Particuology. 6(4): 271-275 (2008). [cited by applicant]
Morales-Cruz et al., “Two-step nanoprecipitation for the production of protein-loaded PLGA nanospheres,” Results Pharma Sci. 2: 79-85 (2012). [cited by applicant]
Mueller et al., “The rheology of suspensions of solid particles,” Proc R Soc A. 466: 1201-1228 (2010). [cited by applicant]
Naqvi et al., “Living cell factories—electrosprayed microcapsules and microcarriers for minimally invasive delivery,” Adv Mater. 28(27): 5662-71 (2016)(10 pages). [cited by applicant]
Nguyen et al., “Pharmaceutical applications of electrospraying,” J Pharm Sci. 105(9): 2601-2620 (2016). [cited by applicant]
Park et al., “One step immobilization of protein encapsulated core/shell particles onto nanofibers,” Macromol Mater Eng. 295(6): 544-550 (2010). [cited by applicant]
Patel et al. “Poloxamers: A pharmaceutical excipients with therapeutic behaviors”, 2009, 15, International Journal of PharmTech Research, vol. (1), No. 2, pp. 299-303. [cited by applicant]
Persic, L. et al., “An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries,” Gene; 9-18 (1997). [cited by applicant]
Pivnik, A.V., “Use of rituximab for treatment of HIV-infected patients with hematological disorders,” Genotekhnologiya Medical Center, Moscow, 7 pages; English Abstract Only (2013). [cited by applicant]
Press, O.W. et al., “Monoclonal Antibody 1F5 (Anti-CD20) Serotherapy of Human B Cell Lymphoma,” Blood, vol. 69; No. 2; 584-591 (1987). [cited by applicant]
Reichardt, C., “Solvatochromic Dyes as Solvent Polarity Indicators,” Chem. Rev., vol. 94; 2319-2358 (1994). [cited by applicant]
Richardson, H. et al., “Influence of the glass transition on solvent loss from spin-cast glassy polymer thin films,” Eur. Phys. J. E, vol. 12; 021; S87-S91 (2003). [cited by applicant]
Saglam et al., “Preparation of high protein micro-particles using two-step emulsification,” Food Hydrocolloids. 25(5): 1139-48 (2011). [cited by applicant]
Sblattero, D. and Bradbury, A., “Exploiting recombination in single bacteria to make large phage antibody libraries,” Nature Biotechnology, vol. 18; 75-80 (2000). [cited by applicant]
Serra-Peinado, C., et al., “Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab,” Nature Communications, vol. 10; 15 pages (2019). [cited by applicant]
Shire et al., “Challenges in the development of high protein concentration formulations,” J Pharm Sci. 93(6): 1390-402 (2004). [cited by applicant]
Takats et al., “Electrosonic spray ionization. A gentle technique for generating folded proteins and protein complexes in the gas phase and for studying ion-molecule reactions at atmospheric pressure,” Anal Chem. 76(14)… [cited by applicant]
Torchilin. “Multifunctional nanocarriers,” Adv Drua Deliv Rev. 58(14): 1532-55 (2006). [cited by applicant]
Vehring, “Pharmaceutical particle engineering via spray drying,” Pharm Res. 25(5): 999-1022 (2008). [cited by applicant]
Vonhoff, Sebastian, Thesis: “The Influence of Atomization Conditions on Protein Secondary and Tertiary Structure During Microparticle Formation by Spray-Freezing-Drying,” Doktorgrades Dr. rer. nat, Der Natunvissenschaft… [cited by applicant]
Wang et al., “FDA's regulatory science program for generic PLAI PLGA-based drug products,” Am Phann Rev. <https://www.americanpharmaceuticalrevie,v.com/Featured-Articles/ 188841-FDA-s-Regulatory-Science-Program-for-Gene… [cited by applicant]
Wanning et al., “Pharmaceutical spray freeze drying,” Int J Pharm. 488(1-2): 136-53 (2015). [cited by applicant]
Xie et al., “Encapsulation of protein drugs in biodegradable microparticles by co-axial electrospray,” J Colloid Interface Sci. 317(2): 469-76 (2008). [cited by applicant]
Yuan et al., “Coaxial electrospray of curcumin-loaded microparticles for sustained drug release,” PLoS One. 10(7):e0132609 (2015) (15 pages). [cited by applicant]
Yuan et al., “One-step fabrication of triple-layered rnicrocapsules by a tri-axial flow focusing device for microencapsulation of soluble drugs and imaging agents,” Proc SPIE vol. 9711, Imaging, Manipulation, and Analys… [cited by applicant]
Zhang et al., “Coaxial electrospray ofrnicroparticles and nanoparticles for biomedical applications,” Expert Rev Med Devices. 9(6): 595-612 (2012). [cited by applicant]
Zhiqi, L., et al., “Functional Emulsifiers and Emulsions”, China Light Industry Press, Apr. 30, 2000, 2 pages. [cited by applicant]
Ziabicki et al., “Crystal nucleation in an electric field,” Macromol Symp. 104(1): 65-87 (1996). [cited by applicant]
CN Search report Mailed on Jan. 13, 2024 for CN Application No. 2021800293477. [cited by applicant]
English Translation of CN Office Action Mailed on Jan. 13, 2024 for CN Application No. 2021800293477. [cited by applicant]
English translation of CN Search Report mailed Jan. 13, 2024 for CN Application No. 2021800293477. [cited by applicant]
English translation of Office Action issued in Chinese Patent Application No. 201780072350.0, issued May 17, 2021 (16 pages). [cited by applicant]
Fenn et al., “Electrospray ionization for mass spectrometry of large biomolecules,” Science. 246(4926): 64-71 (Oct. 6, 1989). [cited by applicant]
Mardles. E. W. J., “Viscosity of Suspensions and the Einstein Equation,” Nature. 145: 970 (Jun. 22, 1940). [cited by applicant]
Nema et al., Pharmaceutical Dosage Forms: Parenteral Medications, Third Edition, vol. 3: Requlations, Validation and the Future. Informa Healthcare, vii-304 (2010) (328 pages). [cited by applicant]
Supplementary Partial European Search Report for European Patent Application No. 17873547.8, dated Jun. 15, 2020 (9 pages). [cited by applicant]
U.S. Department of Health and Human Services, “Q3C—Tables and List: Guidance for Industry,” Aug. 2018 (10 pages). [cited by applicant]
Zhang et al., “Coaxial electrospray of ranibizumab-loaded microparticles for sustained release of anti-VEGF therapies,” PloS One. 10(8): e0135608 (2015) (16 pages). [cited by applicant]
Frost, G.I., “Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration,” Expert Opinion Drug Deliv., vol. 4; No. 4; 427-440 (2007). [cited by applicant]
Jun, L., “Guizho Science and Technology Press”, Agricultural building materials, Aug. 31, 1999, 4 pages (Concise explanation met by the English Translation of CN Appl 202080064558 office action provided herewith). [cited by applicant]
Kaltashov et al., “Estimates of Protein Surface Areas in Solution by Electrospray Ionization Mass Spectrometry,” available in PMC Jan. 27, 2009, published in final edited form as: Anal Chem. 77(16): 5370-5379 (2005) (21… [cited by applicant]
Cited By (4)
US 12,433,849 US 12,558,323 US 12,569,445 US 12,600,763